No Data
No Data
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association Dor Cancer Research (AACR) Annual Meeting 2024
Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)SAN DIEGO, March 06, 2024
Cidara Receives $11M Milestone Payment From Partner Mundipharma
Cidara Secures $11.14 Million After EU Drug Approval
Press Release: Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO -- Approval triggered by positive results from ReSTORE Phase III clinical trial -- Pay
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara's Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb. 12, 202
Cidara Therapeutics Granted Nasdaq Listing Extension
No Data